{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéine p120 d'activation de la ras GTPase : Questions médicales les plus fréquentes",
"headline": "Protéine p120 d'activation de la ras GTPase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéine p120 d'activation de la ras GTPase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-16",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéine p120 d'activation de la ras GTPase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines d'activation de la ras GTPase",
"url": "https://questionsmedicales.fr/mesh/D020703",
"about": {
"@type": "MedicalCondition",
"name": "Protéines d'activation de la ras GTPase",
"code": {
"@type": "MedicalCode",
"code": "D020703",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.325.150.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéine p120 d'activation de la ras GTPase",
"alternateName": "p120 GTPase Activating Protein",
"code": {
"@type": "MedicalCode",
"code": "D020729",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "René Rasche",
"url": "https://questionsmedicales.fr/author/Ren%C3%A9%20Rasche",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry, University Münster, Germany."
}
},
{
"@type": "Person",
"name": "Daniel Kümmel",
"url": "https://questionsmedicales.fr/author/Daniel%20K%C3%BCmmel",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry, University Münster, Germany."
}
},
{
"@type": "Person",
"name": "Manil Kanade",
"url": "https://questionsmedicales.fr/author/Manil%20Kanade",
"affiliation": {
"@type": "Organization",
"name": "Indian Institute of Science Education and Research, Pune, India."
}
},
{
"@type": "Person",
"name": "Pananghat Gayathri",
"url": "https://questionsmedicales.fr/author/Pananghat%20Gayathri",
"affiliation": {
"@type": "Organization",
"name": "Indian Institute of Science Education and Research, Pune, India."
}
},
{
"@type": "Person",
"name": "Qingqing Dai",
"url": "https://questionsmedicales.fr/author/Qingqing%20Dai",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Jena, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/36068430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40264-022-01216-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferric Carboxymaltose in Heart Failure with Iron Deficiency.",
"datePublished": "2023-08-26",
"url": "https://questionsmedicales.fr/article/37632463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/NEJMoa2304968"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferric Pyrophosphate Forms Soluble Iron Coordination Complexes with Zinc Compounds and Solubilizing Agents in Extruded Rice and Predicts Increased Iron Solubility and Bioavailability in Young Women.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36931746",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tjnut.2022.12.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35947351",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-022-02242-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.",
"datePublished": "2022-07-06",
"url": "https://questionsmedicales.fr/article/35790696",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12185-022-03401-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Régulateurs des protéines G",
"item": "https://questionsmedicales.fr/mesh/D020555"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines d'activation de la GTPase",
"item": "https://questionsmedicales.fr/mesh/D020690"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines d'activation de la ras GTPase",
"item": "https://questionsmedicales.fr/mesh/D020703"
},
{
"@type": "ListItem",
"position": 8,
"name": "Protéine p120 d'activation de la ras GTPase",
"item": "https://questionsmedicales.fr/mesh/D020729"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéine p120 d'activation de la ras GTPase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéine p120 d'activation de la ras GTPase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéine p120 d'activation de la ras GTPase",
"description": "Comment diagnostiquer une anomalie de p120 GTPase ?\nQuels tests sont utilisés pour évaluer p120 GTPase ?\nY a-t-il des biomarqueurs associés à p120 GTPase ?\nQuels symptômes peuvent indiquer un problème avec p120 ?\nComment les mutations de p120 sont-elles détectées ?",
"url": "https://questionsmedicales.fr/mesh/D020729?mesh_terms=Ferric+Compounds#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéine p120 d'activation de la ras GTPase",
"description": "Quels symptômes sont liés à une dysfonction de p120 GTPase ?\nLa dysfonction de p120 peut-elle causer des cancers ?\nQuels types de cancers sont liés à p120 GTPase ?\nY a-t-il des signes précoces de dysfonction de p120 ?\nComment p120 affecte-t-il la signalisation cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D020729?mesh_terms=Ferric+Compounds#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéine p120 d'activation de la ras GTPase",
"description": "Peut-on prévenir les mutations de p120 ?\nY a-t-il des mesures préventives pour le cancer lié à p120 ?\nComment l'alimentation influence-t-elle p120 ?\nLe tabagisme affecte-t-il p120 GTPase ?\nL'exercice physique peut-il aider à prévenir les cancers ?",
"url": "https://questionsmedicales.fr/mesh/D020729?mesh_terms=Ferric+Compounds#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéine p120 d'activation de la ras GTPase",
"description": "Quels traitements ciblent p120 GTPase ?\nPeut-on utiliser des médicaments pour moduler p120 ?\nY a-t-il des essais cliniques pour p120 ?\nComment la thérapie génique peut-elle aider ?\nQuels sont les effets secondaires des traitements ciblés ?",
"url": "https://questionsmedicales.fr/mesh/D020729?mesh_terms=Ferric+Compounds#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéine p120 d'activation de la ras GTPase",
"description": "Quelles complications peuvent survenir avec p120 ?\nComment p120 affecte-t-il le pronostic du cancer ?\nY a-t-il des complications liées aux traitements de p120 ?\nLes mutations de p120 augmentent-elles le risque de récidive ?\nQuelles sont les implications des anomalies de p120 ?",
"url": "https://questionsmedicales.fr/mesh/D020729?mesh_terms=Ferric+Compounds#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéine p120 d'activation de la ras GTPase",
"description": "Quels sont les facteurs de risque pour les mutations de p120 ?\nL'âge est-il un facteur de risque pour p120 ?\nLes antécédents familiaux influencent-ils p120 ?\nLe stress peut-il affecter p120 GTPase ?\nY a-t-il des expositions environnementales à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D020729?mesh_terms=Ferric+Compounds#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de p120 GTPase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses protéomiques peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer p120 GTPase ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'immunoblotting et la PCR pour détecter les mutations."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à p120 GTPase ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de p120 peuvent servir de biomarqueurs dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec p120 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies de croissance cellulaire ou des cancers peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment les mutations de p120 sont-elles détectées ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations peuvent être détectées par séquençage génétique et analyses fonctionnelles."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction de p120 GTPase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles de croissance et des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "La dysfonction de p120 peut-elle causer des cancers ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans p120 sont associées à divers types de cancers."
}
},
{
"@type": "Question",
"name": "Quels types de cancers sont liés à p120 GTPase ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers comme le cancer du poumon et le mélanome sont souvent associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes précoces de dysfonction de p120 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes précoces peuvent inclure des anomalies dans le développement cellulaire."
}
},
{
"@type": "Question",
"name": "Comment p120 affecte-t-il la signalisation cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "p120 régule la signalisation en activant les GTPases, influençant la prolifération."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les mutations de p120 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention des mutations est difficile, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour le cancer lié à p120 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle p120 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer la santé cellulaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il p120 GTPase ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque de mutations et de cancers associés."
}
},
{
"@type": "Question",
"name": "L'exercice physique peut-il aider à prévenir les cancers ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier est associé à une réduction du risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent p120 GTPase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des inhibiteurs spécifiques sont en développement."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des médicaments pour moduler p120 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent moduler l'activité de p120 dans les cellules."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour p120 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques évaluent des traitements ciblant les anomalies de p120."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique peut-elle aider ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait corriger les mutations de p120 dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ciblés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions immunitaires et des toxicités cellulaires."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec p120 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des cancers avancés et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Comment p120 affecte-t-il le pronostic du cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies de p120 peuvent aggraver le pronostic et la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées aux traitements de p120 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des effets secondaires graves peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les mutations de p120 augmentent-elles le risque de récidive ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations peuvent augmenter le risque de récidive du cancer après traitement."
}
},
{
"@type": "Question",
"name": "Quelles sont les implications des anomalies de p120 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies de p120 peuvent entraîner des troubles de croissance et des cancers."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les mutations de p120 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour p120 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de mutations et de cancers associés augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils p120 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de mutations."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter p120 GTPase ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut influencer la régulation de p120 et augmenter les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des expositions environnementales à surveiller ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des agents cancérigènes peut augmenter le risque de mutations."
}
}
]
}
]
}
Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada; Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.
Publications dans "Protéine p120 d'activation de la ras GTPase" :
Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada; Research Institute, McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: tomoko.takano@mcgill.ca.
Publications dans "Protéine p120 d'activation de la ras GTPase" :
Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-Environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.
Publications dans "Protéine p120 d'activation de la ras GTPase" :
Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-Environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.
Publications dans "Protéine p120 d'activation de la ras GTPase" :
The intravenous iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) offer the possibility of administering a large amount of iron in one infusion. This results in faster corre...
Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart failure with a reduced ejection fraction and iron deficiency. Additional evidence about the effec...
In this double-blind, randomized trial, we assigned ambulatory patients with heart failure, a left ventricular ejection fraction of 40% or less, and iron deficiency, in a 1:1 ratio, to receive intrave...
We enrolled 3065 patients, of whom 1532 were randomly assigned to the ferric carboxymaltose group and 1533 to the placebo group. Death by month 12 occurred in 131 patients (8.6%) in the ferric carboxy...
Among ambulatory patients who had heart failure with a reduced ejection fraction and iron deficiency, there was no apparent difference between ferric carboxymaltose and placebo with respect to the hie...
Co-extrusion of ferric pyrophosphate (FePP) with solubilizers, citric acid/trisodium citrate (CA/TSC), or ethylenediaminetetraacetic acid (EDTA) sharply increases iron absorption. Whether this can pro...
Our objectives were to 1) investigate the ligand coordination of iron, zinc, and solubilizers in extruded rice and test associations with iron solubility and absorption, 2) assess whether co-extrusion...
We produced labeled...
The addition of zinc and solubilizers created new iron coordination complexes of Fe(III) species with a weak ligand field at a high-spin state that correlated with solubility (r...
Rice extrusion of FePP with solubilizers resulted in bioavailable iron coordination complexes. In the case of FePP + CA/TSC, PA exerted similar inhibition of FIA as with FeSO...
Intravenous (IV) iron is the preferred treatment for patients with iron deficiency anemia (IDA) who require rapid replenishment of iron stores or in whom oral iron is not tolerated or effective. Data ...
RCTs reporting the incidence of blindly adjudicated cardiovascular events in IDA patients treated with IV iron were identified by systematic literature review (SLR). Pairwise random effects meta-analy...
The SLR retrieved 694 unique articles, of which four were RCTs reporting the incidence of the composite cardiovascular endpoint; two studies comparing FCM (N = 1529) with IS (N = 1505), and two studie...
Pooling data from four large-scale RCTs suggested that FDI was associated with significantly lower incidence of cardiovascular adverse events compared to both FCM and IS....
A multicenter, randomized, open-label, phase III study was conducted to compare the efficacy and safety of intravenous ferric derisomaltose (FDI) versus saccharated ferric oxide (SFO) in Japanese pati...
Bioremediation provides an environmentally sound solution for hydrocarbon removal. Although bioremediation under anoxic conditions is slow, it can be coupled with methanogenesis and is suitable for en...
The randomized IronIC trial evaluated the effect of intravenous ferric derisomaltose on physical capacity in iron-deficient, maintenance heart transplant (HTx) recipients. Iron deficiency was defined ...
We assessed key governors of iron homeostasis, such as hepcidin, soluble transferrin receptor (sTfR), and interleukin-6 (IL-6). We also measured growth factors and inflammatory markers with relevance ...
Hepcidin did not differ between HTx recipients and controls, even though markers of inflammation were modestly elevated. However, HTx recipients with ferritin <30 μg/L or sTfR above the reference rang...
HTx recipients with iron deficiency as defined in heart failure do not have elevated hepcidin levels, although inflammatory markers are modestly increased. The high ferritin cut-offs used in heart fai...
In this study, a fast, reproducible and simple-to-apply a new potentiometric determination method was developed for the evaluation of iron (III) reducing power (FRAP), one of the antioxidant capacity ...
The heterogeneous Fenton-like reaction (HeFR) has always been a research focus for environmental applications. However, it has long been difficult to reach a consensus on the reaction mechanism becaus...
Cardiovascular diseases are a leading cause of mortality and morbidity worldwide. Aberrant thrombosis is a common feature of systemic conditions like diabetes and obesity, and chronic inflammatory dis...